Drugs / IBI301
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02945215 | Dec 2016 → Mar 2019 | B-cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02867566 | Aug 2016 → Sep 2019 | diffuse large B-cell lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02867566 ↗ |
| Modality | Monoclonal antibody | “IBI301 is a recombinant chimeric murine/human anti-CD20 monoclonal antibody” PMID 33751401 ↗ Mar 2021 |
| Route | Intravenous | “IBI301: 375 mg/m2, IV” NCT02867566 ↗ |